Novavax
$14.249876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$14.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.19 (+9.12%) As of 3:59 PM EDT today
+$1.19 (+9.12%) Today
Why Robinhood?
You can buy or sell Novavax and other stocks, options, ETFs, and crypto commission-free!
About NVAX
Novavax, Inc. Common Stock, also called Novavax, is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. Read More It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Employees
165
Headquarters
Gaithersburg, Maryland
Founded
1987
Market Cap
605.46M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
9.33M
High Today
$14.47
Low Today
$12.87
Open Price
$13.34
Volume
6.32M
52 Week High
$17.71
52 Week Low
$3.54
Collections
NVAX News
ReutersMar 28
Edited Transcript of NVAX earnings conference call or presentation 11-Mar-20 8:30pm GMT
Q4 2019 Novavax Inc Earnings Call
ROCKVILLE Mar 28, 2020 (Thomson StreetEvents) -- Edited Transcript of Novavax Inc earnings conference call or presentation We
Analyst Ratings
57%
of 7 ratings
Buy
57%
Hold
29%
Sell
14%
NVAX Earnings
-$1.69
-$1.13
-$0.56
$0.00
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected Apr 30, After Hours
